Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Offers $100K Grants. The Catch: Takers Must Give Up First License Rights

NEW YORK, Jan. 8 — Invitrogen has launched a grant program to support tool development for life-science research, the company said on Tuesday.


The San Diego-based company will offer one-year grants of between $25,000 and $100,000 for research into molecular biology enzymes; functional analysis; separation technology, purification technology, and amplification; labeling; and quantitation techniques.


Funding decisions will be made by a committee that includes Invitrogen researchers and undisclosed molecular biologists.


The project's first deadline, covering projects in enzymes for molecular and cell biology, is March 1. Deadlines for proposals in other fields are scheduled quarterly through the rest of the year.


Invitrogen said it will accept applications from researchers at academic institutions, not-for-profit organizations, and startup biotechs. The company will retain first rights to license any inventions that emerge from these projects.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.